Unlock instant, AI-driven research and patent intelligence for your innovation.

eoc315 Mod.I crystalline compound and preparation method thereof

A compound and crystal form technology, applied in the application field of EOC315Mod.I crystal form in pharmaceuticals, can solve the problem of not finding the EOC315 crystal form, and achieve the effects of long tumor progression time, long survival time, and high response speed.

Active Publication Date: 2022-08-05
TAIZHOU EOC PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no public reports related to the crystal form of EOC315 have been found, and the present invention discloses the Mod.I crystal form of EOC315 for pharmaceutical research for the first time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • eoc315 Mod.I crystalline compound and preparation method thereof
  • eoc315 Mod.I crystalline compound and preparation method thereof
  • eoc315 Mod.I crystalline compound and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1 Preparation of EOC315Mod.I crystalline compound

[0067] The preparation of EOC315Mod.I type crystalline compound includes the following steps:

[0068] 1) 9g EOC315 base was dissolved in 90mL methanol to make EOC315 solution, 2.5g methanesulfonic acid was dissolved in 16mL methanol to make methanesulfonic acid solution;

[0069] 2) Begin at 50°C, add the methanesulfonic acid solution dropwise to the EOC315 solution, and continue heating for 15 minutes after dropping;

[0070] 3) The filtrate was distilled under reduced pressure, after steaming out part of the solvent, 200 ml of isopropanol was added to continue the distillation under reduced pressure until the feed liquid was about 250 mL, cooling and crystallization for 1 hour, suction filtration, and the filter cake was collected.

[0071] 4) Vacuum drying at 45°C to obtain EOC315Mod.I crystalline compound, the yield is 90.5-96.3%, and the purity is 99.1-99.9%.

[0072] Using X-ray diffraction analysis, ...

Embodiment 2

[0073] Example 2 Analysis of the EOC315Mod.I crystalline compound of Example 1 by differential scanning calorimetry (DSC)

[0074] The DSC trace was recorded in an aluminum pan at a heating rate of 10°C / min under a nitrogen atmosphere. It was measured that the EOC315 obtained in Example 1 had a sharp endothermic peak at 200.7°C, indicating that the EOC315 was a single Mod.I crystal form with a melting point of 200.7°C. The analysis results are as image 3 .

[0075] As is known to those of ordinary skill in the art, the melting temperature determined depends on the experimental conditions, especially the heating rate used. In addition, the melting temperature is affected by the purity of the substance. The reported melting temperatures were determined with a product that was at least 98.5% pure.

Embodiment 3

[0076] Example 3 Analysis of the EOC315Mod.I crystalline compound of Example 1 by X powder diffraction

[0077] X-ray powder diffraction data were recorded with germanium-induced monochromatic CuKα1-radiation at room temperature. At room temperature, 2θ scans were performed with an angular resolution of 0.08° between 3°≤2θ≤35° (step size 0.5°) using a small linear position-sensitive detector. X-ray powder diffraction pattern as figure 1 , where the 2θ and d(A) values ​​are shown in Table 1.

[0078] One of ordinary skill in the art will appreciate that the obtained X-ray diffraction pattern may have measurement errors, which depend on the measurement conditions. In particular, it is generally known that the intensity of an X-ray diffraction pattern may fluctuate depending on the crystal habit of a substance and the measurement conditions used. In addition, the measurement error of the diffraction angle θ of a conventional X-ray diffraction pattern at a given temperature is...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
melting pointaaaaaaaaaa
transition temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a 4-(4-chloroanilino)-7-(2-methylaminocarbonyl-4-oxymethyl)pyridyl furo[2,3-d]pyridazine mesylate (EOC315) The preparation method of Mod.I crystal form compound, crystal form characterization and medicinal use thereof.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to the preparation and characterization of an EOC315Mod.I crystal form compound, and also relates to the application of the EOC315Mod.I crystal form in pharmacy. Background technique [0002] EOC315 (4-(4-Chloroanilino)-7-(2-methylaminocarbonyl-4-oxomethyl)pyridylfuro[2,3-d]pyridazine mesylate) is not currently available in any country listed. American biopharmaceutical company ACT Biotech, Inc. (ACTBiotech, hereinafter referred to as ACT) obtained the license of EOC315 from Bayer HealthCare Pharmaceuticals in 2008. In January 2014, Edding signed an asset purchase agreement with ACT to obtain its global exclusive rights . Its structural formula is as follows: [0003] [0004] EOC315 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase activity with oral bioavailability with an IC50 value of 6 nM as measured by biochemical assays. T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D491/048A61K31/5025A61K31/7068A61P35/00
CPCA61K31/5025A61K31/7068C07D491/048C07B2200/13A61K2300/00A61P35/04A61K33/243C07D491/04
Inventor 李合亭王德强常伟于洪瑞邹晓明
Owner TAIZHOU EOC PHARMA CO LTD